H.C. Wainwright reiterates Aclaris stock rating after trial miss
H.C. Wainwright reiterated a Buy rating and $16.00 price target on Aclaris Therapeutics (ACRS) despite its Phase 2 trial for bosakitug missing primary and secondary endpoints. The stock fell 8% to $3.60 post-announcement. Analysts remain bullish on ACRS's broader pipeline, with a Strong Buy consensus and price targets ranging from $4 to $16.

